Board meeting on Sep 25 to finalise Rights Issue terms

Fund Raising View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹815.30

prior close

₹815.15

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.8%+2.1% vs market

Pharmaceuticals peers, median of 173sector+0.5%+2.4% vs sector

On the reaction day the stock moved 2.1 pts more than Nifty Smallcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+1.2

15m

+0.6

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9+0.8+2.1+0.5+2.4

Next day

+3.3-0.6+3.9-0.5+3.8

+2.6-0.6+3.2-0.2+2.8

+1.6-2.2+3.7-0.9+2.5

+3.3-2.8+6.2-0.5+3.9

+1.3-2.5+3.8-2.0+3.3

+0.8-3.3+4.1-3.3+4.1

15d

-3.7-3.5-0.2-4.9+1.2

-3.1-10.3+7.2-9.8+6.7

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma's board will meet on 25 September 2026 to finalise terms of its Rights Issue approved earlier. The issue, worth up to Rs 1,300 crores, will comprise equity shares of face value Rs 2. Agenda items include the issue price, entitlement ratio, record date, payment mechanism, and timing of the issue. Trading window is closed from 23 September till 48 hours after the outcome is announced.

Likely market impact

Rights Issue terms nearing finalisation; outcome may influence stock price and shareholder participation decisions.